Your session is about to expire
← Back to Search
DNA Plasmid Therapy
30 mg dose of JVS-100 for Heart Failure (STOP-HF Trial)
Phase 2
Waitlist Available
Research Sponsored by Juventas Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
STOP-HF Trial Summary
This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.
Eligible Conditions
- Heart Failure
STOP-HF Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Impact of JVS-100 injection on Quality of Life at 4 month follow-up
Impact of JVS-100 injection on Six Minute Walk Distance (6MWD) at 4 month follow-up
Secondary outcome measures
Impact of JVS-100 Injection on LVEF
Impact of JVS-100 Injection on Major Adverse Cardiac Events
Impact of JVS-100 Injection on NYHA class
+4 moreSTOP-HF Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: 30 mg dose of JVS-100Experimental Treatment1 Intervention
30 mg dose of JVS-100
Group II: 15 mg dose of JVS-100Experimental Treatment1 Intervention
15 mg dose of JVS-100
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Juventas Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
422 Total Patients Enrolled
3 Trials studying Heart Failure
254 Patients Enrolled for Heart Failure
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger